Aurinia Pharmaceuticals (FRA:IKAP) Common Stock : €1,111.3 Mil (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Common Stock?

Aurinia Pharmaceuticals's quarterly common stock declined from Sep. 2023 (€1,123.1 Mil) to Dec. 2023 (€1,100.6 Mil) but then increased from Dec. 2023 (€1,100.6 Mil) to Mar. 2024 (€1,111.3 Mil).

Aurinia Pharmaceuticals's annual common stock increased from Dec. 2021 (€1,041.7 Mil) to Dec. 2022 (€1,118.9 Mil) but then declined from Dec. 2022 (€1,118.9 Mil) to Dec. 2023 (€1,100.6 Mil).

Aurinia Pharmaceuticals Common Stock Historical Data

The historical data trend for Aurinia Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Common Stock Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

671.84

776.24

1,041.69

1,118.93

1,100.60

Aurinia Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															1,114.28	1,104.35	1,123.05	1,100.60	1,111.34

Aurinia Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Aurinia Pharmaceuticals (FRA:IKAP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

AUPH:USA IKAP:Germany

Address

4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals (FRA:IKAP) Headlines

No Headlines